Clay Siegall is the founder, president, CEO, and chairman of Seattle Genetics. He founded the company in 1998 and has been the CEO for the 19 years that the firm has been in operation. Seattle Genetics was established on the premises of innovative scientific research. Clay, a trained scientist in the biomedical field had a passion for developing new medicines and treatments for patients. This passion prompted him to establish the firm. A critical analysis of the company reveals that the corporation is an extension of its founder both in policy and practice.
Besides being a medical scientist, Clay Siegall is an author where he has over 70 publications. He writes across many disciplines. Recently, he has written on the current issue of Trump’s decision to withdraw from the Paris agreement on climate change. The work is posted on his blog website. The last two posts were on: why the republican mayor in Indiana isn’t cheering on the agreement. Here Clay states the reasons why the mayor is not in support of the president’s decision. The second article is on the Electric Power Giant’s criticism of the president’s decision to withdraw from Paris climate agreement.
Clay’s Role at Seattle Genetics
At Seattle Genetics, Clay Siegall plays a critical role where under his leadership, the company has been approved to produce ADC products and ADCETRIS. ACEDTRIS has become a global brand and is now approved in more than 65 countries. He has also pioneered the company to acquire strategic licenses for the company’s ADC technology.
His contribution towards the cancer research community
Clay Siegall is committed to finding out a cancer therapy that is both effective and efficient. The firm is doing thorough research to ensure they develop a drug that will be able to fight and destroy cancerous cells only as opposed to other medicines. The primary objective of the company is put their patients under medication that won’t have harmful side effects to their body.
Clay has also played key roles in helping Seattle Genetics raise more than $1.2 billion through public and private financing. The capital infusion has allowed the company to continue making advancement in cancer research treatments. These achievements can be attributed to Clay Siegall’s combination of exemplary leadership skills and scientific skills.